Prime Highlights:
- New trial shows that Mounjaro achieves 20% weight reduction, beating out Wegovy’s 14% at 72 weeks.
- Mounjaro may be worse for the obese because it has a different action.
Key Facts:
- Mounjaro produced quarter of body weight loss in 32% of trial participants, compared with Wegovy’s 16%.
- Mounjaro users shed 18 cm on average around their waistline, and Wegovy users lost 13 cm on average.
- These two drugs had the same side effects but improved blood pressure, sugar, and cholesterol levels.
Key Background:
The first head-to-head test between weight-loss medicines Wegovy (semaglutide) and Mounjaro (tirzepatide) exposed surprising differences in efficacy. The 750-patient study classed Mounjaro as notably more powerful than Wegovy, averaging 20% loss of body weight in 72 weeks compared with Wegovy at 14%. Scientists determined that as Mounjaro twirls two levers in the brain to curtail hunger and Wegovy flips one, it was the better medicine.
The Eli Lilly-funded trial discovered that 32% of the patients who received Mounjaro lost a quarter of their body weight, and they also had lower waist circumference, blood pressure, blood glucose, and cholesterol. The findings were revealed at the European Congress on Obesity and the New England Journal of Medicine. Both medicines had the same side effects, but more preferable outcomes in Mounjaro indicate that it can be more effective for patients with greater percentages of obesity.
The outcome of the trial also indicated that the females lost more weight than males. While Mounjaro is being prescribed more and more privately, replacing Wegovy in the UK, Wegovy is increasingly being employed for uses such as prevention of heart disease, which has not yet been established in Mounjaro trials. Such experts as Glasgow University’s Prof Naveed Sattar has said that while Mounjaro can be more suitable to those who wish to lose as much weight as possible, both drugs are suitable for patients.
There is ongoing research with weight-reduction medication, with new interventions and procedures under trial, e.g., pills and high dose. Prof Sattar tells us that the new discipline would experience advances in avertability of obesity in the not-too-distant future, while he emphasizes improvement in society’s health would be the driving force in achieving long-term control of obesity.
Read More – Click Here
